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ABSTRACT 
Glaucoma is a condition in which distinctive changes occur in the optic nerve and visual field. In glaucoma intraocular pressure (IOP) is raised 
that compresses and damages the optic nerve. As the optic nerve is damaged, it fails to carry the visual information to the brain which induce 
clinically progressive loss of peripheral visual field and ultimately loss of vision. Aims and Objectives: To Evaluate the drug utilization and 
prescribing pattern of drugs used for treatment of glaucoma, to analyze current prescribing trends in anti-glaucoma drugs, to perform a drug 
utilization study, to identify drugs per prescription, category wise identification of drugs prescribed, mono therapy vs combination therapy. 
Materials and Methods: The present study was a prospective, observational study carried out in 105 patients at Shri Mahant Indiresh 
Hospital, Dehradun, Uttarakhand, India. Results: Out of total 105 patients, 68 were males (64.76%) and 37 were females (35.24%). The most 
common age group was 46-60 years. Patients were mostly affected by primary open angle glaucoma (95.23%) then angle closer glaucoma 
(4.76%). Total 184 drugs were prescribed in the treatment of glaucoma. Average number of drugs per prescription was 1.75. Combination 
therapy was prescribed in 51.43% patients & most common used combination therapy was combination of Brimonidine+ timolol (81.48%) 
followed by Bimatoprost+ timolol (18.52%). Monotherapy was used in 48.57% patients in which drug dorzolamide (22.31%) was prescribed 
mostly which is belongs to the category of carbonic anhydrase inhibitors followed by timolol (19.23%) (β- blockers) which was second line 
choice of drug. Generic drugs were mostly prescribed in 77 patients (73.33%) followed by 28 patients (26.66%) were brand names. 
Conclusion: The prescription analysis of glaucoma patients concluded that monotherapy with dorzolamide was the first line choice for 
glaucoma therapy and timolol was found to be the second line choice. Timolol+ brimonidine was the mostly prescribed combination of drug. It 
also showed that all drugs were prescribed in their generic name instead of brand name.   
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INTRODUCTION  
Glaucoma is a condition in which distinctive changes occur 
in the optic nerve and visual field. It is characterized by 
raised intraocular pressure (IOP) that compresses and 
damages the optic nerve. As the optic nerve is damaged, it 
fails to carry the visual information to the brain which cause 
clinically progressive loss of peripheral visual field and 
ultimately loss of vision. [1] 
Glaucoma is not a single disease entity but it’s a group of eye 
diseases characterized by anatomical features, such as open 
angle where the anterior chamber angle of the eye remains 
open and angle closure where anterior chamber angle 
remains closed. [2] 
There is so many risk factors to cause glaucoma such as, 
High intraocular pressure, age more than 60 years, family 
history of glaucoma, systemic conditions like diabetes, heart 
disease, high blood pressure and sickle cell anemia, eye 
condition like near sightedness, and topical administration 
of steroids for a long time. It is difficult to detect optic nerve 
damage in early stages of the disease. [3] 
Treatment of glaucoma depends on the type of disease. It 
can be treated with eye drops, oral pills, laser, open surgical 
procedure, or a combination of methods. The whole purpose 
of treatment is to prevent further loss of vision. This is 
imperative as loss of vision due to glaucoma is irreversible. 
Keeping the IOP (intra ocular pressure) under control is the 
main key factor in preventing the loss of vision from 
glaucoma. [4] 
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Drug therapy is an important component of patient care 
management in health care settings. Many pharmaceutical 
products are available in the market often having 
unaffordable cost. Irrational use of drugs and dosage forms 
result in potential adverse effects to the patients and cause 
financial burden. To avoid such problems, every member of 
the healthcare system should practice rational use of drugs. 
So, drug utilization study is important criteria to avoid the 
irrationality of drugs. [5] 
Evaluation of drug utilization pattern is considered powerful 
means to find out the role of drugs in society as well as to 
increase the therapeutic efficacy and the cost-effectiveness 
of therapy in medical practices. In addition, periodic auditing 
of drug utilization pattern also provides feedback to the 
prescribers and helps to decrease the occurrence of 
untoward adverse effects due to the use of medicines. [6] 
MATERIAL AND METHODS: 
A prospective study was conducted at a tertiary care 
hospital in Dehradun, Uttarakhand for a duration of 6 
months. After getting approval from the ethics committee of 
the hospital, subjects were selected based on inclusion & 
exclusion criteria.   
Inclusion criteria:  
 Patients visiting at Outpatient Department of 
Ophthalmology for the treatment of glaucoma. 
 Patients with either sex (male and female). 
 Patients more than 18 years of age. 
 Patients willing to participate in the study. 
Exclusion criteria: 
 Patients not willing to participate in the study. 
 Patients less than 18 years of age. 
 Patients who are diagnosed with other 
ophthalmological condition/ surgery. 
Signed inform consent was obtained from all 
participants prior to the study. Data was collected from 
the patients using self-designed structured data 
collection form to assess the drug utilization pattern 
and prescribing pattern of glaucoma medication. Other 
relevant information on the disease, prevalence, 
diagnosis, treatment plan was collected. 
RESULTS: 
1. Gender wise distribution of patients 
Out of 105 glaucoma patients, 64.76% (n=68) were male & 
35.24% (n=37) were female as shown in table 1 and figure 1. 
Table 1: Gender wise distribution of patients 
Category  Number of patients (%) 
(n=105) 
Male  68(64.76%) 
Female 37(35.24%) 
 
 
Figure 1: Gender wise distribution of patients 
Age wise distribution of patients 
Out of 105 patients, the maximum patients belong to age 
group between 46-60 which were 64.76% as shown in table 
2 and figure 2. 
Table 2: Age wise distribution of patients 
Age (Years) Number of patients (%) 
(n=105) 
30-45 15(14.28%) 
46-60 68(64.76%) 
>60 22(20.95%) 
 
 
Figure 2: Age wise distribution of patients 
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Pattern of glaucoma (n=105 patients) 
Among 105 patients, open angle glaucoma accounted for 95.23% (n=100) & Angle closure glaucoma 4.76 % (n=5) as shown in 
table 3 and figure 3.  
Table 3: Pattern of glaucoma (n=105 patients) 
Types of Glaucoma Frequency Percentage 
Open angle glaucoma- 
Primary open angle glaucoma 
100 95.23% 
Close angle glaucoma- 
Angle closure glaucoma 
5 4.76% 
 
 
Figure 3: Pattern of glaucoma (n=105 patients) 
2. Drugs prescribed for glaucoma  
Among 105 patients, total of 184 drugs were prescribed for the treatment of open and close angle glaucoma as shown in table 4 
& figure 4. 
Table 4: Drugs prescribed for glaucoma 
S.No. Name of Drug Generic Name No. of drugs (%) 
(n= 184) 
1 Betaxolol  Betaxolol  3 (1.63%) 
2 Dorzox  Dorzolamide  29 (15.76%) 
3 Pilocarpine  Pilocarpine 5 (2.72%) 
4 Brimolol  Brimolol  1 (0.54%) 
5 Timolol  Timolol  25 (13.59%) 
6 Bidine LS Brimonidine  7 (3.80%) 
7 Bidine T Brimonidine + timolol 44 (23.91%) 
8 Veldrop  Carboxymethylcellulose  22 (11.96%) 
9 Mannitol  Mannitol  6 (3.26%) 
10 Azopt Brinzolamide  2 (1.09%) 
11 Travo  Travoprast  1 (0.54%) 
12 Acetazolamide Acetazolamide 24 (13.04%) 
13 Bimatoprost  Bimatoprost  1 (0.54%) 
14 Lubrex  Carboxymethyl cellulolose 3 (1.63%) 
15 Latanoprost  Latanoprost 1 (0.54%) 
16 Gonfort  Bimatoprost + timolol 10 (5.43%) 
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Figure 4: Drugs prescribed for glaucoma 
3. Prescribing pattern of drugs (Monotherapy) for glaucoma 
By analysing the prescription pattern of glaucoma patients, the most commonly drugs (monotherapy) were dorzolamide 
(22.31%) which belong to the category of carbonic anhydrase as shown in table 5 & figure 5. 
Table 5: Prescribing pattern of drugs (Monotherapy) for glaucoma 
Drug name % of total single drugs (n=130) 
Brimonidine  7 (5.38%) 
Dorzolamide  29 (22.31%) 
Betaxolol  3 (2.31%) 
Pilocarpine  5 (3.85%) 
Brimolol  1 (0.77%) 
Timolol 25 (19.23%) 
Brinzolamide  2 (1.54%) 
Travoprost  1 (0.77%) 
Acetazolamide 24 (18.46%) 
Bimatoprost  1 (0.77%) 
Latanoprost  1 (0.77%) 
Mannitol  6 (4.61%) 
Carboxymethylcellulose  25 (19.23%) 
 
 
Figure 5: Prescribing pattern of drugs (monotherapy) for glaucoma 
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4. Prescribing pattern of drugs (combination 
therapy) for glaucoma 
The most commonly combination drug were Brimonidine+ 
timolol (79.63%) followed by Bimatoprost+ timolol 
(20.37%) as shown in table 6 & figure 6. 
Table 6: Prescribing pattern of drugs (combination 
therapy) for glaucoma 
Drug name % of total combination 
drugs (n=54) 
Brimonidine+ timolol 44 (81.48%) 
Bimatoprost+ timolol 10 (18.52%) 
 
 
Figure 6: Prescribing pattern of drugs (combination 
therapy) for glaucoma 
5. Average no. of drugs prescribed per prescription 
Among 105 patients, two drugs (44.76%) per prescription 
were mostly prescribed and average no of drug per 
prescription was 1.75 as shown in table 7 & figure 7. 
Table 7: Average no. of drugs prescribed per 
prescription 
Number of drugs per 
prescription 
Number of prescriptions (%) 
 (n=105) 
One  42(40%) 
Two  47 (44.76%) 
Three  16 (15.23%) 
 
 
Figure 7: Average no. of drugs prescribed per 
prescription 
6. Category wise identification of drugs prescribed 
Out of 214 drugs, 32.24% were β- blockers followed by 
25.70% carbonic anhydrase, 23.83% alpha 2 agonists, 
11.68% cellulose derivatives, 2.80% osmotic diuretics, 
2.34% cholinergic agonists & 1.40% prostaglandin 
analogues as shown in table 8 & figure 8.
 
 
Table 8: Category wise identification of drugs prescribed 
Drug Category  No. of drugs (%) 
(n=184) 
β- blockers 55 (29.89%) 
Carbonic anhydrase 55 (29.89%) 
Prostaglandin analogues 8 (4.35%) 
Alpha 2 agonists 30 (16.30%) 
Cholinergic agonists 5 (2.72%) 
Osmotic diuretics 6 (3.26%) 
Cellulose derivatives 25 (13.59%) 
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Figure 8: Category wise identification of drugs prescribed 
 
7. Comparison between monotherapy vs combination 
therapy 
Present study revealed that most of the patients were 
treated with combination therapy (60%) followed by 
monotherapy (40%) as shown in table 9 & figure 9. 
Table 9: Comparison between monotherapy vs 
combination therapy 
Therapy No. of patients  
(n= 105) 
Percentage (%) 
Monotherapy 51 48.57% 
Combination therapy 54 51.43% 
 
 
Figure 9: Comparison between monotherapy vs 
combination therapy 
8. Distribution of anti-glaucoma drugs prescribed by 
generic and brand name. 
Out of 105 patients, majority of drugs were prescribed by 
generic name (73.33%) followed by brand name (26.66%) 
as shown in table 10 & figure 10. 
Table 10: Distribution of anti-glaucoma drugs 
prescribed by generic and brand name. 
Drugs Number of patients (%) 
(n=105) 
Generic 77 (73.33%) 
Brand 28 (26.66%) 
 
 
Figure 10: Distribution of anti-glaucoma drugs 
prescribed by generic and brand name 
DISCUSSION 
The following discussion is based on the data collected from 
a prospective study conducted on 105 patients of glaucoma. 
Different anti glaucoma drugs are prescribed in the clinical 
practice for the treatment of glaucoma. Pharmacologically 
these drugs are categorized in two classes – 1. reduction of 
aqueous humor secretion, 2. enhancement of aqueous 
outflow.  The drug categories include, 
parasympathomimetic, carbonic anhydrase inhibitors 
(CAI’s), α-agonists, β- blockers and Prostaglandin analogues. 
Drug utilization studies are routinely carried out to promote 
rational use of drug and it also prevents unnecessary drug 
use, expense & potential hazards.  
In the present prospective study on drug utilization pattern 
of glaucoma medication, out of 105 glaucoma patients, Open 
angle glaucoma is prevalent in 95.23% patients followed by 
4.76% in closed angle glaucoma respectively this study is 
similar to the study Lulu Bahiyya U.I et al  in which out of 
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222 glaucoma patients, Open angle glaucoma is prevalent in 
91% patients followed by 7% in closed angle glaucoma and 
2% in Normal tension glaucoma respectively [7].  
In the present study 64.76% were male & 35.24% female 
and this finding is quite similar to the study of Patel B. 
Kaushal et al which showed that out of total 101 patients, 71 
were males (70.29%) and 30 were females (29.70%).  [8]   
Maximum patients were in the age group of 46- 60 which 
also encountered in study by Ahmed Q S. et al in which out of 
170 patients, all patients are divided into three age groups, 
1) <40yrs 2) 40-60 yrs 3) >60 yrs. Maximum patients 94 
(55.29%) were between the age group of 40-60yrs. In this 
age group 62(65.95%) were female while 32(34.04%) were 
male. [9].  
Most commonly, two number of drugs per prescription 
(44.76%) was prescribed and average no. of drug per 
prescription was 1.75. The same study shown by Latha C 
Deepa et al which showed that out of total 50 prescriptions, 
the average number of drugs per prescription was 2.02[1], 
Patel B. Kaushal et al which showed that out of total 101 
patients, average number of drugs per prescription was 2 
(45%) which includes Tab. Acetazolamide and Bimatoprost 
drops (19% of Patients), Brimonidine Drops and Betaxolol 
Drops (13% of patients) Tab. Acetazolamide and Pilocarpine 
drops (4% of Patients)[8] & Mahajan H M et al showed that 
out of 405 record assessed, average number of drugs per 
prescription was 1.8. [10]  
Our study show 48.57% patients received monotherapy 
which is quite similar to study by Rai S et al in which 
monotherapy was prescribed to 48 patients (64.86%) [11] & 
out of 184 drugs, total no of 130 drugs were prescribed in 
monotherapy & most frequently prescribed group of drugs 
came out to be carbonic anhydrase inhibitors (29.89%) 
which is different from the study by Nazia P et al which 
analysed out of 116 glaucoma patients, amongst the 
medications, beta blockers were prescribed the most 
(38.12%), followed by carbonic anhydrase inhibitors (both 
oral and topical) and prostaglandin F2α analogues (14.36% 
each). The less commonly prescribed medicines were α2 
agonists, cholinergic drugs, glycerol and antimicrobials [12].   
Among all carbonic anhydrase inhibitors most commonly 
prescribed drug was dorzolamide (22.31%) followed by 
acetazolamide (18.46%) and brinzolamide (1.54%). This 
study is different from the study by Advani M. et al in which 
dorzolamide, a topical carbonic anhydrase inhibitor was the 
second most common drug prescribed in present study 
(23%) of which 15% was with timolol as FDC and the 
remaining (8%) in combination with brimonidine [13]. 
After that, β- blockers were prescribed mostly in which 
timolol was most frequently prescribed drug (19.23%) as 
also noted by Rai S et al in which out of 74 case records, 
most commonly prescribed topical medication was timolol 
0.5% solution (29.16%) followed by bimatoprost 0.03% 
solution (20.83%) [11] & Yadav A. K et al in which out of total 
297 drugs prescribed, timolol was found to be the most 
frequently prescribed drug constituting 82.22% of total 
prescriptions. [14]  
Αlpha 2 agonists (brimonidine, brimolol) formed 16.30%, 
prostaglandin analogue (travoprost, Bimatoprost, 
latanoprost) formed 4.35%, cholinergic agonists 
(pilocarpine) formed 2.72%, osmotic diuretics (mannitol) 
formed 3.26% & cellulose derivatives 
(carboxymethylcellulose) formed 13.59% of total 
prescriptions.  
Out of 105 patients, 51.43% patients (54 patients) received 
combination therapy. This study is quite similar to study by 
Ahmed Q S. et al in which combination therapy was 
prescribed to 53 patients (45.69% of total prescriptions) [9].  
In combination therapy, out of 184 drugs only 54 drugs were 
prescribed in combination drug in which Brimonidine+ 
timolol (81.48%) was most common prescribed drug which 
is similar to study by Patel B. Kaushal et al in which most 
commonly used fixed dose combination was Brimonidine + 
Timolol which was used in 87 (86.1%) of patients [8] 
different from study by Yadav A. K et al in which Timolol and 
acetazolamide (17.22%) was most commonly prescribed 
drug combination followed by timolol and dorzolamide 
(9.44%) [14] followed by Bimatoprost+ timolol (18.52%). 
In the present study 73.33% of the drugs were prescribed by 
generic name while 26.66% were prescribed by their brand 
names which is higher than 0 -10% as reported by other 
Indian studies such as Lulu Bahiyya U.I et al in which [7] and 
Ahmed Q S. et al [9] in which 100% drugs were prescribed by 
brand names.  
In the present study 73.33% of the drugs were prescribed by 
generic name while 26.66% were prescribed by their brand 
names which is higher than 0 -10% as reported by other 
Indian studies such as Lulu Bahiyya U.I et al in which [7] and 
Ahmed Q S. et al [9] in which 100% drugs were prescribed by 
brand names.  
CONCLUSION 
 From the study conducted at Shri Mahant Indiresh Hospital, 
monotherapy with dorzolamide was the first line choice for 
glaucoma and timolol was found to be the second line choice. 
Most of the fixed drug combinations found were 
brimonidine+ timolol. The prescription analysis showed that 
most of the drugs were prescribed in their generic name. 
From the study, it is evident that the male populations are 
more prone to glaucoma as compared to female. Open angle 
glaucoma is prevalent in 95.23% (n=100) patients than 
Angle closure glaucoma and mostly affected age group was 
between 46-60 years. Out study indicates that generic names 
were mostly prescribed then brand names. So, less 
awareness is required related to generic drug prescription. 
These findings vary from region to region, no generalization 
can be made. However, these inferences may provide a lead 
for monitoring rational drug usage. For glaucoma whatever 
therapy is chosen, the concept to be kept in mind is that 
glaucoma therapy is lifelong and needs consideration of 
cost-effectiveness and convenience in individual patient. 
There is need to conduct many such studies at regular 
interval at our institute and also at other institutes across 
the India. This is useful for auditing large number of 
prescriptions to find out early signals of the irrational drug 
use. Such study should be followed by education of the 
prescribers on rational drug therapy for benefits and safety 
of the patients. This study provided a general insight into the 
prescribing patterns of ophthalmological products in 
Dehradun (Uttarakhand). Polypharmacy is not seen, and 
prescription errors were minimum in our study which 
concludes with overall impression of rational prescription. 
Thus, periodical auditing of the prescriptions will help to 
measure the impact of the intervention on the prescribing 
pattern and improve rational pharmacotherapeutics. It is 
essential to conduct similar study in future to elucidate 
rational prescribing for treatment of Glaucoma. 
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